SeedBlink Blog

As AI continues to redefine industry standards, few sectors stand to benefit as profoundly as healthcare. With increasing complexity, data overload, and pressure for efficiency, the need for intelligent automation is more urgent than ever.

Founded by Rishi Wadhera, Shahir Raja, and Constantin Gorgan - industry veterans from the London Stock Exchange, Deloitte, and Microsoft - giles® emerged as Romania’s first enterprise-grade ChatGPT-style application. What began as a local initiative has grown into a global venture, now active across Europe, the US, and the Middle East.

In this exclusive interview, we spoke with Rishi Wadhera, CEO of giles®, about the company’s evolution, the healthcare AI boom, and why now is the perfect time to invest in its mission.

1. How did the idea for giles® come to life, and what problem were you solving from the beginning?

We started with a very simple goal: improve life at work. It was all about productivity, helping people get their day-to-day tasks done faster, and making the process easier. Around the same time, AI had just hit the mainstream, which was perfect timing for us. We knew we could use this technology to bring our vision to life in a tangible way.

2. Why did you decide to focus exclusively on the healthcare industry?

Our first customer, Regulatory Scientific & Health Solutions (R-S-S), is a leader in health economics and drug development. They asked us to connect to PubMed - the open-access medical database from the US government, with over 40 million articles published by researchers, academics, and practitioners.

While building the MVP for R-S-S, we realized just how big the gap was in this space. We saw a chance to stick to our original mission - improving life at work - while focusing on an industry that’s crying out for efficiency. Plus, we loved that our contribution could indirectly help save lives, support patients, and ease the burden of researchers doing the heavy lifting.

It’s a largely untapped market for what we do. The value is real, and the gains are tangible - as long as we execute well on product and delivery.

3. What’s the biggest differentiator between giles® and other AI platforms like IBM Watson or Google Cloud AI?

While platforms like IBM Watson and Gemini are powerful engines behind the scenes of many AI apps, giles® is different - we’re not just another front. We use those LLMs, sure, but we focus on solving a real problem within healthcare.

What makes us stand out:

• We go beyond surfacing insights from data. Once you've uncovered research insights - say, on cancer drug development - giles® helps you act on them. That means creating tasks in project management tools, compiling documentation, arranging meetings via email, and more. It’s about full-stack workflow, not just chat.
• We're LLM-agnostic. Most tools force you into a closed-source model - your data disappears into a black box. We support open-source LLMs that can run on your own infrastructure, keeping your data secure and within your control. And we have the partnerships to make that kind of deployment easy.
• Today, none of the big players are properly connected to medical databases. That could change, but their models are trained on the internet at large - it’s a broad-brush approach. We’re focused on the nuances of healthcare.
• We’re building tooling that helps researchers verify what AI says. Our current agreement rate is 94% - exceptional in today’s AI landscape - but it’s not 100%. So we’re equipping users with ways to validate outputs quickly and efficiently.
• We’re also building defensibility into the product. Think digital subscription products that encapsulate SME knowledge - things you won’t find easily on the open web. We’re also exposing our capabilities via API for customers who want to embed giles® into their own platforms.
• Lastly, most existing tools in healthcare are narrow SaaS solutions, with maybe a touch of AI. We’re conversation-first. giles® becomes a digital teammate - you talk to it like a colleague, to investigate, plan, and act.

4. How does giles®work in practice? What does implementation look like for a pharma company or hospital?

The healthcare ecosystem is huge. We're starting with medical research - particularly drug development. Researchers often need to pull data from public databases and their own internal documentation. giles® becomes the team member that helps them do that.

You talk to it. Ask it for insights, summaries, and opinions, and it delivers. Then, we go a step further. Once you’ve got those insights, giles® can help you structure the next phase: create tasks, collaborate with teammates, build out documentation, ensure compliance, and even loop in your sales systems for eventual distribution.

Soon, we’ll enable voice as well, speak to giles® and it speaks back. Down the line, we’ll also support hospital use cases - everything from appointment coordination to symptom analysis using layman-friendly language, in any language.

5. How do you ensure data accuracy, and compliance, and avoid AI hallucinations?

That’s one of our core strengths. We’re not building new LLMs, that’s expensive, resource-intensive, and unnecessary. Instead, we’ve developed clever algorithms that make us efficient with the data and context we send to the LLM and are equally smart about interpreting what comes back.

6. What kind of traction have you seen so far in terms of clients, use cases, or international presence?

We’ve been running for just under two years. We're incorporated in the US, UK, and UAE, with our dev center in Bucharest Romania has been incredible for technical talent.

We started with SMBs in the B2B space, particularly in medical research. But we quickly realized there’s a parallel B2C channel in academia, medical students, and faculty. That gives us rapid time-to-market and helps us build mindshare with future professionals who’ll eventually bring giles® into their workplaces.

7. What role has the partnership with Google UK played in your expansion?

Google has been a strategic cornerstone for us over the past year. Out of 38 startups they evaluated in the UK and Ireland, we were one of just three they flagged as having exponential growth potential.

They’re supporting us technically: infrastructure, AI services, and scale, but also in terms of marketing, funding, and go-to-market. They’re helping us connect with their client network, including 18 of the top 20 global pharma companies.

Together, we’re mapping out how to ideate, build, launch, and scale the right way.

8. What’s next for giles®in terms of growth, product, and new partnerships?

We’re being methodical. First up is HEOR: we’re already automating the extraction and workflow built around those datasets. Next is expanding our data connectivity, adding tools that support meta-analysis, and integrating deeper into the regulatory layer of healthcare.

We’re guided by a growing advisory panel that keeps surfacing new opportunities to improve how healthcare professionals work: faster, easier, and better.

9. What makes giles®a strong opportunity for investors and why now?

We’ve been bootstrapped for nearly two years, building a solid team and a product that sells. We’ve locked in domain credibility, strong technical delivery, and partnerships that will help us scale quickly and effectively.

With R-S-S and Google backing us, we’ve got momentum and validation. But to get this rocket off the ground, we need the right funding, and this round gives us a solid 24-month runway.

For investors, this is a chance to come in at an early stage, but with unusually strong foundations and growth prospects. The market is hot, our timing is right, and we’re ready to execute.

Explore the opportunity on SeedBlink.